Jiangsu Hengrui Medicine Company Ltd.

Shanghai Hengrui Pharmaceutical Co., Ltd.

Wuxi Grandchamp Pharmaceutical Technology Co., Ltd.

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Jiangsu Hansoh Pharmaceuticals Co., Ltd.

Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

Yali Wang

Changan Sun

Lianshan Zhang

Jiajian Liu

Aifeng Lv

Jindong Liang

Aifeng Lü

Hengli Yuan

Weikang Tao

Piaoyang Sun

Ling L Zhang

Ying Zhang

Tao Wang

Fanglong Yang

Tao Jiang

Yayuan Fu

Dongbing Cui

Jijun Yuan

Guiyang Jiang

Jianyan Xu

Ang Li

Ruijun Wang

Wentao Wu

Dong Ma

Deyu Liu

Hongwei Wang

Junzhuan Qiu

Ziyong Sun

Liang Zhao

Jiping Zha

Feifei Wang

Jingping Wei

Xiang Zeng

Aifeng Lu

Yulu Dai

Chunqian Fang

Aifeng Lue

Aifeng LÜ

Provided is an acylated derivative of human insulin or an analogue thereof. Specifically disclosed is an acylated derivative of a human insulin analogue, or zinc complex thereof; the human insulin analogue being derivatized is preferably Des(B30) human insulin; the acylated derivative is longer-lasting than existing insulin analogues and acylated derivatives thereof, its blood glucose reduction is more steady, and it is more stable in storage.

Acylated derivative of human insulin or analogue thereof

Ligand-cytotoxic drug conjugates, pharmaceutical compositions, preparation methods, and pharmaceutical uses thereof are provided. More specifically, a ligand-cytotoxic drug conjugate of general formula Pc-(X-Y-D)is provided. The ligand-cytotoxic drug conjugate can be used to treat cancer via receptor modulation.

Ligand-cytotoxic drug conjugate, preparation method thereof, and uses thereof

Provided are an anti-c-Met antibody or an antigen binding fragment thereof, and an anti-c-Met antibody-cytotoxic drug conjugate, wherein the antibody or antigen binding fragment thereof is a chimeric antibody or a humanized antibody. Also provided are pharmaceutical compositions containing the humanized anti-c-Met antibody or antigen binding fragment thereof, the antibody-cytotoxic drug conjugate, or pharmaceutically acceptable salts or solvents thereof, that are used in the treatment of cancer.

Anti-c-Met antibody and anti-c-Met antibody-cytotoxic drug conjugate and pharmaceutical use thereof

The present invention provides a human insulin analog, an acylated derivative thereof and a physiologically acceptable salt. The present invention further provides a preparation method for the insulin analog and an application of the insulin analog as a therapeutic agent, and particularly as a diabetes mellitus therapeutic agent.

Human insulin analogue and acylated derivative thereof

The present invention discloses a modified exendin or pharmaceutically acceptable salts thereof, wherein the modified exendin comprises an amino acid sequence having at least 90% sequence identity to SEQ ID No. 17 and the amino acid sequence has a higher stability than the non-modified exendin of SEQ ID No. 4. These compounds are useful in treating type 2 diabetes as GLP-1 receptor agonists.

Modified exendins and uses thereof

What is provided is EPO mimetic peptide derivatives defined as formula (I) and their pharmaceutical salts, the preparation thereof, wherein R, R, R, R, R, n, nare defined as described in description. A composition comprising of an EPO mimetic peptide derivative defined as formula (I) and its pharmaceutical salt. The uses of the derivatives and their pharmaceutical salts, as well as the uses of the compositions described above in treatment of diseases characterized by a deficiency of EPO or a low or defective red blood cell population.R&#x2014;R&#x2014;(CH)&#x2014;R&#x2014;(CH)&#x2014;R&#x2014;R&#x2003;&#x2003;(I)

Erythropoietin mimetic peptide derivative and its pharmaceutical salts, the preparation and uses thereof

This invention discloses GLP-1 analogues and their pharmaceutical salts, wherein the GLP-1 analogue comprises an amino acid sequence of general formula (I), wherein Lys represents a modified lysine with a lipophilic acid. The GLP-1 analogues provided by this invention have the function of human GLP-1, and a longer half-life in vivo compared with the human GLP-1. Uses of such compounds and compositions include treating non-insulin-dependent diabetes, insulin-dependent diabetes, and obesity.X-X-Glu-Gly-Thr-Phe-Thr-Ser-Asp-X-Ser-X-X-X-Glu-X-X-Ala-X-X-X-Phe-Ile-X-Trp-Leu-X-X-X-X-X-X-X-X-X-X-X-X-X-Lys&#x2003;&#x2003;Formula (I)&#x2014;SEQ ID NO: 238

GLP-1 analogues and their pharmaceutical salts and uses

Novel exendins with modifications at one or more of following positions: 2, 14, 27 or 28 and polyethylene glycol derivatives thereof are provided. These compounds are useful in treating type 2 diabetes as GLP-1 receptor agonists.

Modified exedins and uses thereof

Growing community of inventors

Shanghai, China

Yali Wang